CX3CR1 and atherosclerosis: In terms of metabolic outcomes, previous reports using a CX3CR1-deficient model have documented reduced atherosclerosis (on an ApoE-null background)43, 44 and disrupted beta cell function31 but have generally not found differences in energy balance or insulin sensitivity32, 45, 46 though none of these investigations included female mice.